Trulieve Reports Third Quarter 2026 Results
Third quarter revenue of $230 million, with 64% gross marginCash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026Received final DEA registrations pursuant to final order rescheduling state licensed medical marijuana to Schedule III under the Controlled Substances ActTALLAHASSEE, Fla., Nov. 5, 2026 /CNW/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced its results for the quarter ended September 30, 2026. Results are reported in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may